机构:[1]Yan’an Hospital Affiliated to Kunming Medical University/Yan’an Hospital of Kunming City, Kunming, Yunnan 650051, China[2]Key Laboratory of Tumor Immunological Prevention and Treatment of Yunnan Province, Kunming, Yunnan 650051, China[3]Yunnan Cell Biology and Clinical Translational Research Center, Kunming, Yunnan 650051, China[4]Kunming Key Laboratory of Biotherapy, Kunming, Yunnan 650051, China[5]Department of Cancer Biotherapy Center, Yunnan Cancer Hospital/The Third Affiliated Hospital of Kunming Medical University, Kunming 650118, China[6]Department of Pathology, Guangdong Provincial People’s Hospital/Guangdong Academy of Medical Sciences, 106, Zhongshan Road II, Guangzhou 510000, China
This work was supported by the National Natural Science Foundation of China (Grant Nos. 81960499, 81360245, 81660477); the Yunnan Province Science and Technology Department of Kunming Medical University (Grant No. 202001AY070001-168); the Science and Technology Fund of Yunnan Province (Grant No. 2017IB020); and the Science and Technology Fund of Kunming City (Grant No. 2019-1-N- 25318000002027).
第一作者机构:[1]Yan’an Hospital Affiliated to Kunming Medical University/Yan’an Hospital of Kunming City, Kunming, Yunnan 650051, China[2]Key Laboratory of Tumor Immunological Prevention and Treatment of Yunnan Province, Kunming, Yunnan 650051, China[3]Yunnan Cell Biology and Clinical Translational Research Center, Kunming, Yunnan 650051, China[4]Kunming Key Laboratory of Biotherapy, Kunming, Yunnan 650051, China
通讯作者:
通讯机构:[1]Yan’an Hospital Affiliated to Kunming Medical University/Yan’an Hospital of Kunming City, Kunming, Yunnan 650051, China[2]Key Laboratory of Tumor Immunological Prevention and Treatment of Yunnan Province, Kunming, Yunnan 650051, China[3]Yunnan Cell Biology and Clinical Translational Research Center, Kunming, Yunnan 650051, China[4]Kunming Key Laboratory of Biotherapy, Kunming, Yunnan 650051, China[*1]Yan’an Hospital Affiliated to Kunming Medical University/Yan’an Hospital of Kunming City, Kunming, Yunnan 650051, China.
推荐引用方式(GB/T 7714):
Lin Zhuying,Yang Songlin,Zhou Yong,et al.OLFM4 depletion sensitizes gallbladder cancer cells to cisplatin through the ARL6IP1/caspase-3 axis.[J].TRANSLATIONAL ONCOLOGY.2022,16:doi:10.1016/j.tranon.2021.101331.
APA:
Lin Zhuying,Yang Songlin,Zhou Yong,Hou Zongliu,Li Lin...&Wang Wenju.(2022).OLFM4 depletion sensitizes gallbladder cancer cells to cisplatin through the ARL6IP1/caspase-3 axis..TRANSLATIONAL ONCOLOGY,16,
MLA:
Lin Zhuying,et al."OLFM4 depletion sensitizes gallbladder cancer cells to cisplatin through the ARL6IP1/caspase-3 axis.".TRANSLATIONAL ONCOLOGY 16.(2022)